Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New formulation of MS drug more effective, says Serono
The new formulation of Rebif is said to offer substantial improvement in tolerability and reduction in antibody formation. The primary objective of the study was to compare the
The new formulation of Rebif is said to offer substantial improvement in tolerability and reduction in antibody formation. The primary objective of the study was to compare the
Lodotra provides all the benefits of standard immediate release (IR) prednisone but has the additional advantage of reduced morning stiffness combined with a convenient dosing regimen. Patients with
Vectibix is the first human antibody developed for the treatment of patients whose colorectal cancer has spread after chemotherapy treatments. The therapy targets a protein called the epidermal
The partnership will develop compounds that specifically target the Glucose-Dependent Insulinotropic Receptor, or GDIR. The GDIR is a receptor discovered by Arena that has the potential to stimulate
Trubion is developing TRU-015 with biopharmaceutical company, Wyeth. Upon initiation of this phase IIb study and pursuant to the terms of its collaboration with Wyeth, Trubion will receive
The agreement will enable the two companies to combine a BioInvent therapeutic antibody with InNexus’ SuperAntibody Technology. The SuperAntibody Technology has been developed to improve the potency of
Teva, the world’s largest maker of generic drugs, emphasized the strength of its pipeline at a meeting for investors and analysts. CEO Israel Makov said he was very
Initial results from the study show that AeroLEF provided benefit compared to placebo. However, the difference in effectiveness between the placebo and treatment groups has not yet reached
Patients who received AS1404 on top of standard chemotherapy had a median survival of 14 months, compared with 8.8 months in patients treated with chemotherapy alone. This 5.2-month
Seeking damages of around $5.5 billion, J&J claims that Guidant, now a division of Boston Scientific, broke a merger agreement with J&J by allowing Abbott Laboratories access to